Immunopathogenesis of coronavirus infections: implications for SARS

Stanley Perlman, Ajai A Dandekar, Stanley Perlman, Ajai A Dandekar

Abstract

At the end of 2002, the first cases of severe acute respiratory syndrome (SARS) were reported, and in the following year, SARS resulted in considerable mortality and morbidity worldwide. SARS is caused by a novel species of coronavirus (SARS-CoV) and is the most severe coronavirus-mediated human disease that has been described so far. On the basis of similarities with other coronavirus infections, SARS might, in part, be immune mediated. As discussed in this Review, studies of animals that are infected with other coronaviruses indicate that excessive and sometimes dysregulated responses by macrophages and other pro-inflammatory cells might be particularly important in the pathogenesis of disease that is caused by infection with these viruses. It is hoped that lessons from such studies will help us to understand more about the pathogenesis of SARS in humans and to prevent or control outbreaks of SARS in the future.

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1. The severe-acute-respiratory-syndrome coronavirus genome and…
Figure 1. The severe-acute-respiratory-syndrome coronavirus genome and virion.
a | The severe-acute-respiratory-syndrome coronavirus (SARS-CoV) genome consists of 28 putative open reading frames (ORFs) in 9 mRNA transcripts. ORF1a and ORF1b, which account for about two-thirds of the genome, both encode large polyproteins. ORF1b protein is produced by a –1-base-pair ribosomal frameshift from the reading frame of ORF1a. The SARS-CoV genome encodes four structural proteins: spike (S), envelope (E), matrix (M) and nucleocapsid (N). In non-human isolates, transcription of ORF8a and ORF8b produces a single protein. b | A schematic representation of a SARS-CoV virion is shown. ssRNA, single-stranded RNA.
Figure 2. Macrophage infection and antibody-dependent enhancement…
Figure 2. Macrophage infection and antibody-dependent enhancement of virus entry in infection with feline infectious peritonitis virus.
a | Infection of macrophages and possibly dendritic cells (DCs) results in both dissemination of feline infectious peritonitis virus (FIPV) infection and dysregulation of these cells, leading to lymphocyte apoptosis. b | FIPV usually infects cells through the binding of the spike protein to its cellular receptor, CD13. The virus is then internalized and released into the cytoplasm. c | In antibody-dependent entry, specific antibodies bind the spike protein. The antibody-opsonized FIPV virions then interact with FcγRs (receptors for IgG). Some evidence indicates that this process augments the normal spike–CD13 interaction. After binding of the opsonized virions to FcγRs, the virus is internalized and released into the cytoplasm. Antigen–antibody complexes are also deposited in the vasculature, resulting in complement activation. Activation of complement contributes to the development of vasculitis and oedema, with death of the animal occurring soon after. C3, complement component 3; IL-10, interleukin-10; TH2 cell, T helper 2 cell; TNF, tumour-necrosis factor.
Figure 3. Mechanisms of immune-mediated demyelination in…
Figure 3. Mechanisms of immune-mediated demyelination in infection with murine hepatitis virus.
In immunocompetent mice, infection of glial cells (that is, astrocytes, microglia and oligodendrocytes) results in migration of T cells into the central nervous system (a). Myelin destruction is mediated by CD4+ and CD8+ T cells, and these cells activate macrophages by the production of cytokines (b) or kill infected cells directly (c), both of which result in demyelination. In recombination-activating gene 1 (Rag1−/−) mice, which lack T and B cells, two additional mechanisms of demyelination have been elucidated. Rag1−/− mice do not develop demyelination when infected with the JHM strain of murine hepatitis virus (MHV-JHM); as occurs in immunocompetent mice, demyelination develops after the adoptive transfer of MHV-JHM-specific T cells. However, demyelination also results if infected Rag1−/− mice are infected with a recombinant MHV-JHM expressing the macrophage attractant CC-chemokine ligand 2 (CCL2) (d), presumably by direct activation of macrophages. Similarly, exogenous delivery of neutralizing MHV-JHM-specific antibody (e) results in macrophage activation and demyelination; this process depends on activation through complement and activating Fcg receptors (receptors for IgG). TCR, T-cell receptor.
Figure 4. Infection with murine hepatitis virus…
Figure 4. Infection with murine hepatitis virus strain 3 results in upregulation of expression of fibrinogen-like protein 2.
Murine hepatitis virus strain 3 (MHV-3) becomes internalized after binding macrophages through its receptor, CD66 (a). Subsequent to internalization, virions are uncoated and begin to replicate. As part of the replication process (b), the nucleocapsid protein is synthesized. Subsequently, a signalling pathway involving p38 mitogen-activated protein kinase (p38MAPK) activation, as well as the nucleocapsid protein and other unknown host factors, is initiated (c), resulting, ultimately, in binding of the transcription factor hepatocyte nuclear factor 4α (HNF4α) to the gene that encodes fibrinogen-like protein 2 (FGL2) (d), which is a prothrombinase. The FGL2 protein that is produced then translocates to the cell surface (e), where it induces fibrin deposition and, consequently, acute liver necrosis.

References

    1. Griffin DE. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 1995;191:117–134.
    1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 2005;5:215–229. doi: 10.1038/nri1573.
    1. Mejias A, Chavez-Bueno S, Ramilo O. Respiratory syncytial virus pneumonia: mechanisms of inflammation and prolonged airway hyperresponsiveness. Curr. Opin. Infect. Dis. 2005;18:199–204. doi: 10.1097/01.qco.0000168378.07110.72.
    1. Banerjee S, Narayanan K, Mizutani T, Makino S. Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells. J. Virol. 2002;76:5937–5948. doi: 10.1128/JVI.76.12.5937-5948.2002.
    1. Menasche G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol. Rev. 2005;203:165–179. doi: 10.1111/j.0105-2896.2005.00224.x.
    1. Parr RL, et al. Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity. J. Virol. 1995;69:5033–5038.
    1. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature Med. 2004;10:S88–S97. doi: 10.1038/nm1143.
    1. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N. Engl. J. Med. 2003;349:2431–2441. doi: 10.1056/NEJMra032498.
    1. Lai MMC, Cavanagh D. The molecular biology of coronaviruses. Adv. Virus Res. 1997;48:1–100. doi: 10.1016/S0065-3527(08)60286-9.
    1. van der Hoek L, et al. Identification of a new human coronavirus. Nature Med. 2004;10:368–373. doi: 10.1038/nm1024.
    1. Fouchier RA, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl Acad. Sci. USA. 2004;101:6212–6216. doi: 10.1073/pnas.0400762101.
    1. Woo PC, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 2005;79:884–895. doi: 10.1128/JVI.79.2.884-895.2005.
    1. Guan Y, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278. doi: 10.1126/science.1087139.
    1. Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science303, 1666–1669 (2004). References 13 and 14 trace the evolution of SARS-CoV in human and masked palm-civet populations.
    1. Song HD, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl Acad. Sci. USA. 2005;102:2430–2435. doi: 10.1073/pnas.0409608102.
    1. Hamming I, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. doi: 10.1002/path.1570.
    1. Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
    1. Kuba K, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med. 2005;11:875–879. doi: 10.1038/nm1267.
    1. Imai Y, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116. doi: 10.1038/nature03712.
    1. Wong RS, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326:1358–1362. doi: 10.1136/bmj.326.7403.1358.
    1. Wang JT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg. Infect. Dis. 2004;10:818–824. doi: 10.3201/eid1005.030640.
    1. Nicholls JM, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–1778. doi: 10.1016/S0140-6736(03)13413-7.
    1. Chan KH, et al. Detection of SARS coronavirus in patients with suspected SARS. Emerg. Infect. Dis. 2004;10:294–299. doi: 10.3201/eid1002.030610.
    1. Peiris JS, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772. doi: 10.1016/S0140-6736(03)13412-5.
    1. Gu J, et al. Multiple organ infection and the pathogenesis of SARS. J. Exp. Med. 2005;202:415–424. doi: 10.1084/jem.20050828.
    1. Farcas GA, et al. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J. Infect. Dis. 2005;191:193–197. doi: 10.1086/426870.
    1. Mazzulli T, et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg. Infect. Dis. 2004;10:20–24. doi: 10.3201/eid1001.030404.
    1. Lamontagne L, Descoteaux JP, Jolicoeur P. Mouse hepatitis virus 3 replication in T and B lymphocytes correlate with viral pathogenicity. J. Immunol. 1989;142:4458–4465.
    1. Franks TJ, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum. Pathol. 2003;34:743–748. doi: 10.1016/S0046-8177(03)00367-8.
    1. Cheung CY, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 2005;79:7819–7826. doi: 10.1128/JVI.79.12.7819-7826.2005.
    1. Yilla M, et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res. 2005;107:93–101. doi: 10.1016/j.virusres.2004.09.004.
    1. Tseng CT, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J. Immunol. 2005;174:7977–7985. doi: 10.4049/jimmunol.174.12.7977.
    1. Spiegel M, et al. Inhibition of β interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J. Virol. 2005;79:2079–2086. doi: 10.1128/JVI.79.4.2079-2086.2005.
    1. Law HK, et al. Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells. Blood. 2005;106:2366–2374. doi: 10.1182/blood-2004-10-4166.
    1. Wong CK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95–103. doi: 10.1111/j.1365-2249.2004.02415.x.
    1. Wang WK, et al. Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome. Clin. Infect. Dis. 2004;39:1071–1075. doi: 10.1086/423808.
    1. Zhang Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect. Immun. 2004;72:4410–4415. doi: 10.1128/IAI.72.8.4410-4415.2004.
    1. Tsui PT, Kwok ML, Yuen H, Lai ST. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg. Infect. Dis. 2003;9:1064–1069. doi: 10.3201/eid0909.030362.
    1. Lee CH, et al. Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome. J. Immunol. 2004;172:7841–7847. doi: 10.4049/jimmunol.172.12.7841.
    1. de Groot RJ, Horzinek MC. The Coronaviridae. 1995. pp. 293–315.
    1. Stoddart CA, Scott FW. Intrinsic resistance of feline peritoneal macrophages to coronavirus infection correlates with in vivo virulence. J. Virol. 1989;63:436–440.
    1. de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot RJ. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J. Virol. 2005;79:1036–1044. doi: 10.1128/JVI.79.2.1036-1044.2005.
    1. Hoskins JD. Coronavirus infection in cats. Vet. Clin. North Am. Small Anim. Pract. 1993;23:1–16. doi: 10.1016/S0195-5616(93)50001-3.
    1. Tresnan DB, Levis R, Holmes KV. Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I. J. Virol. 1996;70:8669–8674.
    1. Dean GA, Olivry T, Stanton C, Pedersen NC. In vivo cytokine response to experimental feline infectious peritonitis virus infection. Vet. Microbiol. 2003;97:1–12. doi: 10.1016/j.vetmic.2003.08.010.
    1. Haagmans B, Egberink H, Horzinek M. Apoptosis and T-cell depletion during feline infectious peritonitis. J. Virol. 1996;70:8977–8983.
    1. Kipar A, et al. Histopathological alterations of lymphatic tissues in cats without feline infectious peritonitis after long-term exposure to FIP virus. Vet. Microbiol. 1999;69:131–137. doi: 10.1016/S0378-1135(99)00101-7.
    1. Zheng L, et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348–351. doi: 10.1038/377348a0.
    1. Kiss I, Poland AM, Pedersen NC. Disease outcome and cytokine responses in cats immunized with an avirulent feline infectious peritonitis virus (FIPV)-UCD1 and challenge-exposed with virulent FIPV-UCD8. J. Feline Med. Surg. 2004;6:89–97. doi: 10.1016/j.jfms.2003.08.009.
    1. Kipar A, Kohler K, Leukert W, Reinacher M. A comparison of lymphatic tissues from cats with spontaneous feline infectious peritonitis (FIP), cats with FIP virus infection but no FIP, and cats with no infection. J. Comp. Pathol. 2001;125:182–191. doi: 10.1053/jcpa.2001.0501.
    1. Paltrinieri S, Cammarata MP, Cammarata G, Comazzi S. Some aspects of humoral and cellular immunity in naturally occuring feline infectious peritonitis. Vet. Immunol. Immunopathol. 1998;65:205–220. doi: 10.1016/S0165-2427(98)00155-X.
    1. Kipar A, Bellmann S, Kremendahl J, Kohler K, Reinacher M. Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis. Vet. Immunol. Immunopathol. 1998;65:243–257. doi: 10.1016/S0165-2427(98)00158-5.
    1. Jacobse-Geels HE, Daha MR, Horzinek MC. Antibody, immune complexes, and complement activity fluctuations in kittens with experimentally induced feline infectious peritonitis. Am. J. Vet. Res. 1982;43:666–670.
    1. Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp. Immunol. Microbiol. Infect. Dis. 1981;4:175–189. doi: 10.1016/0147-9571(81)90003-5.
    1. Vennema H, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 1990;64:1407–1409.
    1. Lavi E, Gilden D, Wroblewska Z, Rorke L, Weiss S. Experimental demyelination produced by the A59 strain of MHV. Neurology. 1984;34:597–603. doi: 10.1212/WNL.34.5.597.
    1. Lampert PW, Sims JK, Kniazeff AJ. Mechanism of demyelination in JHM virus encephalomyelitis. Acta Neuropathol. 1973;24:76–85. doi: 10.1007/BF00691421.
    1. Weiner LP. Pathogenesis of demyelination induced by a mouse hepatitis virus (JHM virus) Arch. Neurol. 1973;28:298–303. doi: 10.1001/archneur.1973.00490230034003.
    1. Stohlman SA, Bergmann CC, Perlman S. Persistent Viral Infections. 1998. pp. 537–557.
    1. Perlman S. Pathogenesis of coronavirus-induced infections: review of pathological and immunological aspects. Adv. Exp. Med. Biol. 1998;440:503–513. doi: 10.1007/978-1-4615-5331-1_65.
    1. Bergmann CC, et al. Perforin and γ interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. J. Virol. 2004;78:1739–1750. doi: 10.1128/JVI.78.4.1739-1750.2004.
    1. Wu GF, Perlman S. Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neurotropic coronavirus. J. Virol. 1999;73:8771–8780.
    1. Wang F, Stohlman SA, Fleming JO. Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated. J. Neuroimmunol. 1990;30:31–41. doi: 10.1016/0165-5728(90)90050-W.
    1. Houtman JJ, Fleming JO. Dissociation of demyelination and viral clearance in congenitally immunodeficient mice infected with murine coronavirus JHM. J. Neurovirol. 1996;2:101–110. doi: 10.3109/13550289609146543.
    1. Lin MT, Hinton DR, Marten NW, Bergmann CC, Stohlman SA. Antibody prevents virus reactivation within the central nervous system. J. Immunol. 1999;162:7358–7368.
    1. Lin MT, Stohlman SA, Hinton DR. Mouse hepatitis virus is cleared from the central nervous systems of mice lacking perforin-mediated cytolysis. J. Virol. 1997;71:383–391.
    1. Parra B, et al. IFN-γ is required for viral clearance from central nervous system oligodendroglia. J. Immunol. 1999;162:1641–1647.
    1. Fleming JO, Trousdale MD, El-Zaatari F, Stohlman SA, Weiner LP. Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J. Virol. 1986;58:869–875.
    1. Watanabe R, Wege H, ter Meulen V. Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature. 1983;305:150–153. doi: 10.1038/305150a0.
    1. Stohlman SA, Hinton DR. Viral induced demyelination. Brain Pathol. 2001;11:92–106. doi: 10.1111/j.1750-3639.2001.tb00384.x.
    1. Wang F-I, Hinton D, Gilmore W, Trousdale M, Fleming JO. Sequential infection of glial cells by the murine hepatitis virus JHM strain (MHV-4) leads to a characteristic distribution of demyelination. Lab. Invest. 1992;66:744–754.
    1. Wu GF, Dandekar AA, Pewe L, Perlman S. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J. Immunol. 2000;165:2278–2286. doi: 10.4049/jimmunol.165.4.2278.
    1. Gombold J, Sutherland R, Lavi E, Paterson Y, Weiss SR. Mouse hepatitis virus A59-induced demyelination can occur in the absence of CD8+ T cells. Microb. Pathog. 1995;18:211–221. doi: 10.1016/S0882-4010(95)90058-6.
    1. Haring JS, Pewe LL, Perlman S. Bystander CD8 T cell-mediated demyelination after viral infection of the central nervous system. J. Immunol. 2002;169:1550–1555. doi: 10.4049/jimmunol.169.3.1550.
    1. Kim TS, Perlman S. Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus. Am. J. Pathol. 2005;166:801–809. doi: 10.1016/S0002-9440(10)62301-2.
    1. Kim TS, Perlman S. Viral expression of CCL2 is sufficient to induce demyelination in RAG1−/− mice infected with a neurotropic coronavirus. J. Virol. 2005;79:7113–7120. doi: 10.1128/JVI.79.11.7113-7120.2005.
    1. Pewe LL, Perlman S. CD8 T cell-mediated demyelination is IFN-γ dependent in mice infected with a neurotropic coronavirus. J. Immunol. 2002;168:1547–1551. doi: 10.4049/jimmunol.168.4.1547.
    1. Pewe L, Haring J, Perlman S. CD4 T-cell-mediated demyelination is increased in the absence of γ interferon in mice infected with mouse hepatitis virus. J. Virol. 2002;76:7329–7333. doi: 10.1128/JVI.76.14.7329-7333.2002.
    1. Chen BP, Kuziel WA, Lane TE. Lack of CCR2 results in increased mortality and impaired leukocyte activation and trafficking following infection of the central nervous system with a neurotropic coronavirus. J. Immunol. 2001;167:4585–4592. doi: 10.4049/jimmunol.167.8.4585.
    1. Glass WG, et al. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. 2004;172:4018–4025. doi: 10.4049/jimmunol.172.7.4018.
    1. Liu MT, Armstrong D, Hamilton TA, Lane TE. Expression of MIG (monokine induced by interferon-γ) is important in T lymphocyte recruitment and host defense following viral infection of the central nervous system. J. Immunol. 2001;166:1790–1795. doi: 10.4049/jimmunol.166.3.1790.
    1. Liu MT, et al. The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J. Immunol. 2000;165:2327–2330. doi: 10.4049/jimmunol.165.5.2327.
    1. Knobler RL, Tunison LA, Oldstone MB. Host genetic control of mouse hepatitis virus type 4 (JHM strain) replication. I. Restriction of virus amplification and spread in macrophages from resistant mice. J. Gen. Virol. 1984;65:1543–1548. doi: 10.1099/0022-1317-65-9-1543.
    1. Xue S, Sun N, van Rooijen N, Perlman S. Depletion of blood-borne macrophages does not reduce demyelination in mice infected with a neurotropic coronavirus. J. Virol. 1999;73:6327–6334.
    1. Yuwaraj S, Cattral M, Pope M, Levy G. Murine hepatitis virus: molecular biology and pathogenesis. Viral Hep. Rev. 1996;2:125–142.
    1. Coutelier JP, et al. B lymphocyte and macrophage expression of carcinoembryonic antigen-related adhesion molecules that serve as receptors for murine coronavirus. Eur. J. Immunol. 1994;24:1383–1390. doi: 10.1002/eji.1830240622.
    1. Pope M, et al. Pattern of disease after murine hepatitis virus strain 3 infection correlates with macrophage activation and not viral replication. J. Virol. 1995;69:5252–5260.
    1. Ding JW, et al. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J. Virol. 1997;71:9223–9230.
    1. Marsden PA, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J. Clin. Invest. 2003;112:58–66. doi: 10.1172/JCI18114.
    1. McGilvray ID, et al. Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgl-2 through p38 mitogen-activated protein kinase activation. J. Biol. Chem. 1998;273:32222–32229. doi: 10.1074/jbc.273.48.32222.
    1. Ning Q, et al. Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4α. J. Biol. Chem. 2003;278:15541–15549. doi: 10.1074/jbc.M212806200.
    1. Raj GD, Jones RC. Infectious bronchitis virus: immunopathogenesis of infection in the chicken. Avian Pathol. 1997;26:677–706. doi: 10.1080/03079459708419246.
    1. Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 2003;32:567–582. doi: 10.1080/03079450310001621198.
    1. Hendley JO. The host response, not the virus, causes the symptoms of the common cold. Clin. Infect. Dis. 1998;26:847–848. doi: 10.1086/513921.
    1. Raj GD, Savage CE, Jones RC. Effect of heterophil depletion by 5-fluorouracil on infectious bronchitis virus infection in chickens. Avian Pathol. 1997;26:427–432. doi: 10.1080/03079459708419224.
    1. Chen BY, Hosi S, Nunoya T, Otakura C. Histopathology and immunochemistry of renal lesions due to infectious bronchitis virus in chickens. Avian Pathol. 1996;25:269–283. doi: 10.1080/03079459608419141.
    1. Lee C, Brown C, Hilt DA, Jackwood MW. Nephropathogenesis of chickens experimentally infected with various strains of infectious bronchitis virus. Avian Pathol. 2004;66:835–840.
    1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N. Engl. J. Med. 2000;342:1334–1349. doi: 10.1056/NEJM200005043421806.
    1. Yang ZY, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl Acad. Sci. USA. 2005;102:797–801. doi: 10.1073/pnas.0409065102.
    1. Subbarao K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 2004;78:3572–3577. doi: 10.1128/JVI.78.7.3572-3577.2004.
    1. Martina BE, et al. SARS virus infection of cats and ferrets. Nature. 2003;425:915. doi: 10.1038/425915a.
    1. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol. 2004;173:4030–4039. doi: 10.4049/jimmunol.173.6.4030.
    1. Roberts A, et al. Severe acute respiratory syndrome coronavirus infection of Golden Syrian hamsters. J. Virol. 2005;79:503–511. doi: 10.1128/JVI.79.1.503-511.2005.
    1. Fouchier RA, et al. Koch's postulates fulfilled for SARS virus. Nature. 2003;423:240. doi: 10.1038/423240a.
    1. Weingartl H, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 2004;78:12672–12676. doi: 10.1128/JVI.78.22.12672-12676.2004.
    1. McAuliffe J, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology. 2004;330:8–15. doi: 10.1016/j.virol.2004.09.030.
    1. Rowe T, et al. Macaque model for severe acute respiratory syndrome. J. Virol. 2004;78:11401–11404. doi: 10.1128/JVI.78.20.11401-11404.2004.
    1. Kuiken T, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263–270. doi: 10.1016/S0140-6736(03)13967-0.
    1. Lassnig C, et al. Development of a transgenic mouse model susceptible to human coronavirus 229E. Proc. Natl Acad. Sci. USA. 2005;102:8275–8280. doi: 10.1073/pnas.0408589102.
    1. Li W, et al. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 2004;78:11429–11433. doi: 10.1128/JVI.78.20.11429-11433.2004.
    1. Dandekar AA, Anghelina D, Perlman S. Bystander CD8 T-cell-mediated demyelination is interferon-γ-dependent in a coronavirus model of multiple sclerosis. Am. J. Pathol. 2004;164:363–369. doi: 10.1016/S0002-9440(10)63126-4.
    1. Goitsuka R, et al. IL-6 activity in feline infectious peritonitis. J. Immunol. 1990;144:2599–2603.
    1. Foley JE, Rand C, Leutenegger C. Inflammation and changes in cytokine levels in neurological feline infectious peritonitis. J. Feline Med. Surg. 2003;5:313–322. doi: 10.1016/S1098-612X(03)00048-2.
    1. Garlinghouse LE, Jr, Smith AL, Holford T. The biological relationship of mouse hepatitis virus (MHV) strains and interferon: in vitro induction and sensitivities. Arch. Virol. 1984;82:19–29. doi: 10.1007/BF01309365.
    1. Pewe L, et al. A severe acute respiratory syndrome-associated coronavirus-specific protein enhances virulence of an attenuated murine coronavirus. J. Virol. 2005;79:11335–11342. doi: 10.1128/JVI.79.17.11335-11342.2005.

Source: PubMed

3
Předplatit